Metformin in women with PCOS, CONS

详细信息    查看全文

• 作者：Marie L. Misso (1)
  Helena J. Teede (1)
  
  1. Monash Centre for Health Research and Implementation ; School Public Health and Preventative Medicine ; Monash University ; MHRP ; 43-51 Kanooka Grove ; Clayton ; VIC ; 3168 ; Australia
  
• 关键词：Polycystic ovary syndrome ; Metformin ; Infertility ; Menstrual cycle regulation ; Hirsutism ; Diabetes and cardiovascular disease risk
• 刊名：Endocrine
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：48
• 期：2
• 页码：428-433
• 全文大小：336 KB
• 参考文献：1. March, WA, Moore, VM, Willson, KJ, Phillips, DI, Norman, RJ, Davies, MJ (2010) The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum. Reprod. 25: pp. 544-551 CrossRef
  2. Boyle, JA, Cunningham, J, O鈥橠ea, K, Dunbar, T, Norman, RJ (2012) Prevalence of polycystic ovary syndrome in a sample of indigenous women in Darwin, Australia. Med. J. Aust. 196: pp. 62-66 CrossRef
  3. Davis, SR, Knight, S, White, V, Claridge, C, Davis, BJ, Bell, R (2002) Preliminary indication of a high prevalence of polycystic ovary syndrome in indigenous Australian women. Gynecol. Endocrinol. 16: pp. 443-446 CrossRef
  4. Hickey, M, Doherty, DA, Atkinson, H, Sloboda, DM, Franks, S, Norman, RJ, Hart, R (2011) Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. Hum. Reprod. 26: pp. 1469-1477 CrossRef
  5. NIH Evidence based workshop on Polycystic Ovary Syndrome. http://prevention.nih.gov/workshops/2012/pcos/resources.aspx. (2012)
  6. Yildiz, BO, Bozdag, G, Yapici, Z, Esinler, I, Yarali, H (2012) Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum. Reprod. (Oxford, England) 27: pp. 3067-3073 CrossRef
  7. Norman, RJRJ, Dewailly, DD, Legro, RSRS, Hickey, TETE (2007) Polycystic ovary syndrome. Lancet 370: pp. 685-697 CrossRef
  8. Teede, HJ, Joham, AE, Paul, E, Moran, LJ, Loxton, D, Jolley, D, Lombard, C (2013) Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity.
  9. Teede, HJ, Misso, ML, Deeks, AA, Moran, LJ, Stuckey, BG, Wong, JL, Norman, RJ, Costello, MF (2011) Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med. J. Aust. 195: pp. S65-S112 CrossRef
  10. Stepto, NK, Cassar, S, Joham, AE, Hutchison, SK, Harrison, CL, Goldstein, RF, Teede, HJ (2013) Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum. Reprod. 28: pp. 777-784 CrossRef
  11. Diamanti-Kandarakis, E, Dunaif, A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr. Rev. 33: pp. 981-1030 CrossRef
  12. Moran, LJ, Misso, ML, Wild, RA, Norman, RJ (2010) Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 16: pp. 347-363 CrossRef
  13. Wild, RA, Carmina, E, Diamanti-Kandarakis, E, Dokras, A, Escobar-Morreale, HF, Futterweit, W, Lobo, R, Norman, RJ, Talbott, E, Dumesic, DA (2010) Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95: pp. 2038-2049 CrossRef
  14. Moran, LJ, Deeks, AA, Gibson-Helm, ME, Teede, HJ (2012) Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome. Hum. Reprod. 27: pp. 2082-2088 CrossRef
  15. Deeks, AA, Gibson-Helm, ME, Paul, E, Teede, HJ (2011) Is having polycystic ovary syndrome a predictor of poor psychological function including anxiety and depression?. Hum. Reprod. 26: pp. 1399-1407 CrossRef
  16. Giudice, LC (2006) Endometrium in PCOS: implantation and predisposition to endocrine CA. Best. Pract. Res. Clin. Endocrinol. Metab. 20: pp. 235-244 CrossRef
  17. Fauser, BCJM, Tarlatzis, BC, Rebar, RW, Legro, RS, Balen, AH, Lobo, R, Carmina, E, Chang, J, Yildiz, BO, Laven, JSE, Boivin, J, Petraglia, F, Wijeyeratne, CN, Norman, RJ, Dunaif, A, Franks, S, Wild, RA, Dumesic, D, Barnhart, K (2012) Consensus on women鈥檚 health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97: pp. 28-38 CrossRef
  18. Teede, HJ, Joham, AE, Paul, E, Moran, LJ, Loxton, D, Jolley, D, Lombard, C (2013) Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity 21: pp. 1526-1532 CrossRef
  19. Pasquali, R (2014) Metformin in women with PCOS. Pros. Endocrine.
  20. PCOS Australian Alliance: Evidence based guidelines for assessment and management of polycystic ovary syndrome. In: Jean Hailes Foundation for Women鈥檚 Health on behalf of the PCOS Australian Alliance Melbourne (2011)
  21. Legro, RS, Arslanian, SA, Ehrmann, DA, Hoeger, KM, Murad, MH, Pasquali, R, Welt, CK (2013) Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 98: pp. 4565-4592 CrossRef
  22. Bridger, T, MacDonald, S, Baltzer, F, Rodd, C (2006) Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch. Pediatr. Adolesc. Med. 160: pp. 241-246 CrossRef
  23. Morin-Papunen, L, Rantala, AS, Unkila-Kallio, L, Tiitinen, A, Hippelainen, M, Perheentupa, A, Tinkanen, H, Bloigu, R, Puukka, K, Ruokonen, A, Tapanainen, JS (2012) Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J. Clin. Endocrinol. Metab. 97: pp. 1492-1500 CrossRef
  24. Romualdi, D, Giuliani, M, Cristello, F, Fulghesu, AM, Selvaggi, L, Lanzone, A, Guido, M (2010) Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertil. Steril. 93: pp. 2303-2310 CrossRef
  25. M. Costello, B. Shrestha, J. Eden, P. Sjoblom, N. Johnson, Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst. Rev. (1), CD005552 (2007)
  26. Jing, Z, Liang-Zhi, X, Tai-Xiang, W, Ying, T, Yu-Jian, J (2008) The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review. Gynecol. Endocrinol. 24: pp. 590-600 CrossRef
  27. Meyer, C, McGrath, B, Teede, H (2007) Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 30: pp. 471-478 CrossRef
  28. Curi, DDG, Fonseca, AM, Marcondes, JAM, Almeida, JAM, Bagnoli, VR, Soares, JM, Baracat, EC (2012) Metformin versus lifestyle changes in treating women with polycystic ovary syndrome. Gynecol. Endocrinol 28: pp. 182-185 CrossRef
  29. Martin, KA, Chang, RJ, Ehrmann, DA, Ibanez, L, Lobo, RA, Rosenfield, RL, Shapiro, J, Montori, VM, Swiglo, BA (2008) Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93: pp. 1105-1120 CrossRef
  30. T. Tang, J.M. Lord, R.J. Norman, E. Yasmin, A.H. Balen, Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst. Rev. 5, CD003053 (2012). doi:10.1002/14651858.CD003053.pub5
  31. Luque-Ramirez, M, Alvarez-Blasco, F, Botella-Carretero, JI, Martinez-Bermejo, E, Lasuncion, MA, Escobar-Morreale, HF (2007) Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92: pp. 2453-2461 CrossRef
  32. Hoeger, KM, Kochman, L, Wixom, N, Craig, K, Miller, RK, Guzick, DS (2004) A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil. Steril. 82: pp. 421-429 CrossRef
  33. Qublan, HS, Yannakoula, EK, Al-Qudah, MA, El-Uri, FI (2007) Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study. Saudi Med. J. 28: pp. 1694-1699
  34. Hoeger, K, Davidson, K, Kochman, L, Cherry, T, Kopin, L, Guzick, DS (2008) The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J. Clin. Endocrinol. Metab. 93: pp. 4299-4306 CrossRef
  35. Popova, P, Ryasantseva, E, Zazerskaya, I, Ivanova, L, Grineva, E (2010) The role of weight loss and metformin in the improvement of menstrual function in overweight and obese women with polycystic ovary syndrome. Diabetes, Obes. Metab. 12: pp. 87
  36. Pasquali, R, Gambineri, A, Biscotti, D, Vicennati, V, Gagliardi, L, Colitta, D, Fiorini, S, Cognigni, GE, Filicori, M, Morselli-Labate, AM (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85: pp. 2767-2774 CrossRef
  37. Sun, X, Zhang, D, Zhang, W (2013) Effect of metformin on ovulation and reproductive outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Arch. Gynecol. Obstet. 288: pp. 423-430 CrossRef
  38. Siebert, TI, Viola, MI, Steyn, DW, Kruger, TF (2012) Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta-analysis. Gynecol. Obstet. Invest. 73: pp. 304-313 CrossRef
  39. Xiao, J, Chen, S, Zhang, C, Chang, S (2012) The effectiveness of metformin ovulation induction treatment in patients with PCOS: a systematic review and meta-analysis. Gynecol. Endocrinol. 28: pp. 956-960 CrossRef
  40. Moresco, T, Genro, V, Schmitz, C, Souza, C, Cunha-Filho, J (2011) Metformin alone or combined with clomiphene citrate in women with polycystic ovary syndrome and infertility: systematic review. Fertil. Steril. 96: pp. S129 CrossRef
  41. Kar, S (2013) Clomiphene citrate, metformin or the combination of both, as first line ovulation induction drug in polycystic ovarian syndrome: a randomised controlled trial. Fertil. Steril 1: pp. S359-S360
  42. Johnson, N (2011) Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome鈥揳 meta-analysis of randomised trials. Aust. N. Z. J. Obstet. Gynaecol. 51: pp. 125-129 CrossRef
  43. Palomba, S, Falbo, A, Sala, GB (2013) Clomiphene citrate, metformin or both for ovulation induction in therapy naive women with polycystic ovary syndrome (PCOS)? A descriptive review. Curr. Drug Ther. 8: pp. 30-37 CrossRef
  44. Machado, RC, Machado, NA, Geber, S (2012) Evaluation of the use of metformin in ovulation result of patients with the polycystic ovary syndrome resistant to isolated use of clomiphene citrate. Jornal Brasileiro de Reproducao Assistida 16: pp. 27-31
  45. Misso, ML, Costello, MF, Garrubba, M, Wong, J, Hart, R, Rombauts, L, Melder, AM, Norman, RJ, Teede, HJ (2013) Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 19: pp. 2-11 CrossRef
  46. Misso, ML, Teede, HJ, Hart, R, Wong, J, Rombauts, L, Melder, AM, Norman, RJ, Costello, MF (2012) Status of clomiphene citrate and metformin for infertility in PCOS. Trends. Endocrinol. Metab. 23: pp. 533-543 CrossRef
  47. Alebic, MS, Bulum, T, Stojanovic, N, Duvnjak, L (2014) Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria. Endocrine.
  48. Ratner, RE, Christophi, CA, Metzger, BE, Dabelea, D, Bennett, PH, Pi-Sunyer, X, Fowler, S, Kahn, SE (2008) Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J. Clin. Endocrinol. Metab. 93: pp. 4774-4779 CrossRef
  49. Esfahanian, F, Zamani, MM, Heshmat, R (2013) Moini nia, F.: Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. J Obstet Gynaecol Res 39: pp. 806-813 CrossRef
  50. Knowler, W, Barrett-Connor, E, Fowler, S, Hamman, R, Lachin, J, Walker, E, Nathan, D (2002) Diabetes Prevention Program Research Group: reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346: pp. 393-403 CrossRef
  51. Rosenzweig, JL, Ferrannini, E, Grundy, SM, Haffner, SM, Heine, RJ, Horton, ES, Kawamori, R (2008) Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93: pp. 3671-3689 CrossRef
  52. Domecq, JP, Prutsky, G, Mullan, RJ, Sundaresh, V, Wang, AT, Erwin, PJ, Welt, C, Ehrmann, D, Montori, VM, Murad, MH (2013) Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism 98: pp. 4646-4654 CrossRef
  53. Teede, H, Deeks, A, Moran, L (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 8: pp. 41 CrossRef
  
• 刊物主题：Endocrinology; Diabetes; Internal Medicine; Science, general;
• 出版者：Springer US
• ISSN：1559-0100

文摘

Metformin has a potential role for insulin resistance in polycystic ovary syndrome(PCOS) and has demonstrated efficacy in diabetes. There are a large number of studies and evidence syntheses comparing metformin with control, lifestyle interventions, the oral contraceptive pill, and clomiphene citrate; however, there is still uncertainty about the effectiveness of metformin in women with PCOS. Here we present a systematic overview of the evidence for the use of metformin in women with PCOS. The evidence suggests that metformin continues to have an unclear roll in PCOS until further well designed; methodologically rigorous effectiveness studies with large sample sizes are conducted, and these should include women across the body mass index (BMI) range.